Heron Therapeutics (HRTX) reported $155M in revenue for fiscal 2025, +7.4% year on year. That ranks #2778 by revenue among 2853 SEC filers and #305 in Healthcare. It posted a net loss of −$20.0M for the same year. Revenue has grown 70.4% a year on average since 2016 ($1.3M then). The fiscal 2025 balance sheet shows $256M in total assets and $28.6M in cash.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerIncludingAssessedTax | $155M | +7.4% | FY20252025-12-31 |
| Gross profitGrossProfit | $114M | +7.5% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$2.5M | +$9.0M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$20.0M | −$6.0M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$27.6M | −$5.1M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $317,000 | −81.4% | FY20252025-12-31 |
| Total assetsAssets | $256M | +9.7% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $14.3M | +$48.0M | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $28.6M | +11.0% | FY20252025-12-31 |
| Long-term debt | Not reported | — |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $34.7M | −$8.1M | Open → |
| Q2 20262026-06-30 | $37.7M | −$5.5M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Heron Therapeutics, Inc.
- Ticker
- HRTX
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0000818033
Filings
- 10-QAug 10, 2026Open filing →
- 10-QMay 11, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Ginkgo BioworksDNA | $170M | −$313,000 |
| MarimedMRMD | $160M | −$14.5M |
| LiquidiaLQDA | $158M | −$68.9M |
| Heron TherapeuticsHRTX | $155M | −$20.0M |
| Airsculpt TechnologiesAIRS | $152M | −$11.7M |
| MacrogenicsMGNX | $150M | −$74,620 |
| NeuroneticsSTIM | $149M | −$39.0M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Heron Therapeutics — Key figures |url=https://companiesranked.com/en/company/heron-therapeutics |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Heron Therapeutics — Key figures. CompaniesRanked. https://companiesranked.com/en/company/heron-therapeuticsBibTeX
@misc{companiesranked-en-company-heron-therapeutics-2026,
author = {{CompaniesRanked}},
title = {{Heron Therapeutics — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/heron-therapeutics}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-073515 · February 26, 2026
{{cite web |title=Heron Therapeutics — Key figures — 10-K (0001193125-26-073515) |url=https://www.sec.gov/Archives/edgar/data/818033/000119312526073515/hrtx-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.